Company / Operating Income per Share
Regeneron Pharmaceuticals Operating Income per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
$31.47
FY2025
5-year range
$19.28 / $36.07
FY2021-FY2025
Trend
-10.5%
vs FY2024
Sector context
#3 of 201
Health Care
What the data says
Among 201 Health Care companies, Regeneron Pharmaceuticals is in the top 1% for operating income per share. Operating Income per Share has fluctuated over the past 10 years, ranging from $11.73 in FY2016 to $36.07 in FY2023.
Based on SEC 10-K filings.
31.47 in FY2025 with a 5-year CAGR of +7.3%. Ranks 3rd among 201 companies in Health Care.
Declined from $36.07 to $31.47 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- +0.4%
- 5-Year CAGR
- +7.3%
- 10-Year CAGR
- -
Sector benchmark
+210.2% above sector average
Key checks
Key Insights
- In FY2025, operating income per share decreased 10.5% year-over-year.
- Ranks #3 out of 201 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2023.
- Lowest operating income per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $31.47 | -10.5% |
| FY2024 | $35.16 | -2.5% |
| FY2023 | $36.07 | +16.1% |
| FY2022 | $31.07 | +61.1% |
| FY2021 | $19.28 | -12.7% |
| FY2020 | $22.08 | +15.8% |
| FY2019 | $19.07 | -12.5% |
| FY2018 | $21.79 | +20.7% |
| FY2017 | $18.05 | +53.8% |
| FY2016 | $11.73 | +4.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026